Anavex Life Sciences Corp.

NasdaqGS:AVXL Stock Report

Mkt Cap: US$820.2m

We’ve recently updated our valuation analysis.

Anavex Life Sciences Valuation

Is AVXL undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for AVXL?

Other financial metrics that can be useful for relative valuation.

AVXL key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDAn/a
PEG Ration/a

Price to Book Ratio vs Peers

How does AVXL's PB Ratio compare to its peers?

The above table shows the PB ratio for AVXL vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average5.4x
BCYC Bicycle Therapeutics
2.9x1.9%US$829.2m
MIRM Mirum Pharmaceuticals
5.2x64.6%US$872.6m
NAMS NewAmsterdam Pharma
5.5x-26.6%US$1.1b
ADMA ADMA Biologics
8.1x60.3%US$810.7m
AVXL Anavex Life Sciences
5.8x53.0%US$820.2m

Price-To-Book vs Peers: AVXL is expensive based on its Price-To-Book Ratio (5.8x) compared to the peer average (5.7x).


Price to Earnings Ratio vs Industry

How does AVXL's PE Ratio compare vs other companies in the US Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a14.0%
n/an/an/a

Price-To-Book vs Industry: AVXL is expensive based on its Price-To-Book Ratio (5.8x) compared to the US Biotechs industry average (1.8x)


Price to Book Ratio vs Fair Ratio

What is AVXL's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

AVXL PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio5.8x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate AVXL's Price-To-Book Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of AVXL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate AVXL's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate AVXL's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst AVXL forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$10.56
US$41.67
+294.6%
15.0%US$50.00US$35.00n/a3
Jan ’24US$9.26
US$32.00
+245.6%
38.7%US$42.00US$11.00n/a4
Dec ’23US$8.87
US$33.25
+274.9%
30.9%US$42.00US$16.00n/a4
Nov ’23US$12.40
US$33.25
+168.1%
30.9%US$42.00US$16.00n/a4
Oct ’23US$10.32
US$33.25
+222.2%
30.9%US$42.00US$16.00n/a4
Sep ’23US$9.65
US$33.25
+244.6%
30.9%US$42.00US$16.00n/a4
Aug ’23US$9.88
US$33.25
+236.5%
30.9%US$42.00US$16.00n/a4
Jul ’23US$10.30
US$33.25
+222.8%
30.9%US$42.00US$16.00n/a4
Jun ’23US$8.24
US$31.00
+276.2%
35.4%US$42.00US$16.00n/a3
May ’23US$8.59
US$31.00
+260.9%
35.4%US$42.00US$16.00n/a3
Apr ’23US$12.64
US$31.00
+145.3%
35.4%US$42.00US$16.00n/a3
Mar ’23US$10.53
US$31.00
+194.4%
35.4%US$42.00US$16.00n/a3
Feb ’23US$11.04
US$30.19
+173.4%
28.8%US$39.00US$16.00n/a4
Jan ’23US$17.34
US$36.58
+111.0%
11.3%US$40.00US$30.75US$9.263
Dec ’22US$17.91
US$36.19
+102.1%
10.1%US$40.00US$30.75US$8.874
Nov ’22US$20.24
US$36.19
+78.8%
10.1%US$40.00US$30.75US$12.404
Oct ’22US$17.95
US$36.19
+101.6%
10.1%US$40.00US$30.75US$10.324
Sep ’22US$20.22
US$36.58
+80.9%
11.3%US$40.00US$30.75US$9.653
Aug ’22US$17.95
US$37.25
+107.5%
8.6%US$40.00US$32.75US$9.883
Jul ’22US$24.57
US$37.25
+51.6%
8.6%US$40.00US$32.75US$10.303
Jun ’22US$12.49
US$20.50
+64.1%
16.3%US$25.00US$17.00US$8.243
May ’22US$12.08
US$21.67
+79.4%
15.7%US$25.00US$17.00US$8.593
Apr ’22US$15.38
US$21.00
+36.5%
19.0%US$25.00US$17.00US$12.642
Mar ’22US$12.94
US$20.67
+59.7%
16.0%US$25.00US$17.00US$10.533
Feb ’22US$6.53
US$13.00
+99.1%
22.6%US$17.00US$10.00US$11.043
Jan ’22US$5.40
US$13.00
+140.7%
22.6%US$17.00US$10.00US$17.343

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies